ClinicalTrials.gg
RecruitingNCT05099172Updated Nov 12, 2026

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

A Phase 1/2 interventional study of BAY2927088_formulation A and BAY2927088_formulation B_1 in Advanced Non-small Cell Lung Cancer, EGFR Mutation and HER2 Mutation, sponsored by Bayer. Recruiting at 94 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Bayer · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.
Updated Oct 21, 2026Primary completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
430
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bayer.

Planned enrollment
6th of 28
430 · median 85
Started
2021
with 1 other
Phase 1/2
2 of 28
2 open now
Registered
18th of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, this one is the 6th largest by planned enrollment, is one of 2 that started in 2021, is one of 2 in phase 1/2, and was the 18th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment, sevabertinib (BAY2927088), is expected to block the mutated EGFR and HER2 proteins which may stop the spread of NSCLC.

The main purpose of this study is to learn:

Escalation, Backfill, and Expansion Part:

  • How safe is BAY2927088 for the participants?
  • What is the highest dose of BAY2927088 that can be tolerated (maximum tolerated dose) by or given to (maximum administered dose) the participants?
  • How does BAY2927088 move into, through, and out of the bodies of the participants?

For this, the researchers will measure the followings:

  • The number of participants with medical problems, also called adverse events and serious adverse events, and their severity
  • The number of participants who discontinue study treatment due to an adverse event.
  • The highest dose of BAY2927088 that the participants can take without having adverse events (maximum tolerated dose (MTD)) or the maximum dose that is tested and found to be safe for the participants in case MTD cannot be found out (maximum administered dose (MAD)) of BAY2927088
  • Number of participants experiencing adverse events that prevent an increase in the dose of BAY2927088 (dose-limiting toxicities (DLTs)) at each dose level
  • The (average) total level of BAY2927088 in the blood (also called AUC) after receiving single or multiple doses of BAY2927088
  • The (average) highest level of BAY2927088 in the blood (also called Cmax) after receiving a single or multiple doses of BAY2927088 Extension Part
  • How well does BAY2927088 work in participants?

For this, the researchers will measure the following:

  • Percentage of participants whose cancer completely disappears (complete response) or reduces by at least 30% (partial response) after taking the treatment (also known as objective response rate (ORR)). This will be assessed by doctors other than the study doctor.

This study has 4 parts:

  • The escalation part aims to find the maximum daily amount (dose) of BAY2927088 that participants can receive.
  • The backfill part aims to test the doses of BAY2927088 that are considered safe in the escalation part by giving it to more participants. This will help find optimal doses of BAY2927088 that work well and are safe to be tested in the next part.
  • The expansion part aims to determine the dose of BAY2927088 to be tested in further studies.
  • The extension part aims to determine whether the selected dose of BAY2927088 from the expansion part works well.

The participants in this study will take the study treatment BAY2927088 in 3-week periods called "cycles". They will in general take BAY2927088 once or twice daily as a liquid/tablet by mouth until their cancer gets worse, they have medical problems, they leave the study, or the study is terminated. Participants will have no more than 5 visits per cycle.

During the study, the study team will:

  • take blood and urine samples,
  • check the status of the cancer by doing computed tomography (CT) or magnetic resonance imaging (MRI) scans,
  • check the participants' overall health and heart health,
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is considered "serious" when it leads to death, puts the participant's life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
  • EGFR Mutation
  • HER2 Mutation
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented or cytologically confirmed locally advanced NSCLC, not suitable for definitive therapy or recurrent or NSCLC at screening (small cell or mixed histologies are excluded).
  • Documented disease progression after treatment with at least one prior systemic therapy for advanced disease. Participants who do not have standard of care access due to any reason, are intolerant to, or are not eligible for standard treatments, may also be eligible.

Note: Except for participants eligible for Group F, Group H and Group I (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.

  • Adequate (ideally taken after last targeted treatment and not older than 6 months) has to be available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.
  • by v1.1 (or by RANO-BM for participants in Expansion Groups G and H) with at least one lesion that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements.
  • Documented activating EGFR and/or mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US] sites) or an equally accredited (outside of the US) local laboratory.
  • (ECOG) performance status 0 or 1.
  • Minimum of 12 weeks.
  • Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 days before the first dose of study treatment:

    1. ≥ 9.0 g/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks prior to testing.
    2. ≥ 100 × 10\^9 cells/L.
    3. ≥ 1.5 ×10\^9 cells/L. Criteria must be met without the use of hematopoietic growth factors (e.g., G-CSF) within 2 weeks prior to testing.
  • Adequate kidney function as assessed by following laboratory test to be conducted within 7 days before the first dose of study treatment:

    a. Estimated (eGFR) > 50 mL/min per 1.73 m\^2 according to the Modification of Diet in renal Disease Study Group (MDRD) formula.

  • Adequate liver function as assessed by following laboratory tests to be conducted within 7 days before the first dose of study treatment:

    1. Total ≤ 1.5 × (or ≤ 3 × ULN for participants with documented Gilbert-Meulengracht Syndrome, or for participants with hyperbilirubinemia considered due to liver metastasis).
    2. and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor).

Exclusion criteria

Exclusion Criteria:

  • Treatment with an EGFR tyrosine kinase inhibitor (TKI) ≤ 8 days or 5x the terminal phase, elimination half-lives, whichever is shorter, prior to the first dose of study drug.
  • Treatment with a systemic anti-cancer treatment (excluding EGFR TKIs as described above) ≤ 14 days prior to the first dose of study drug.
  • Radiation therapy, stereotactic radiosurgery (SRS) and palliative radiation ≤ 14 days prior to the first dose of study drug.
  • Treatment with immunotherapy ≤ 28 days prior to the first dose of study drug.
  • Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Participants with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
  • Any history of primary brain or (symptomatic or asymptomatic), presence of symptomatic central nervous system (CNS) , or that require local treatment (such as radiotherapy or surgery).
  • History of spinal cord compression or brain metastases with the following exceptions:

    1. Participants with treated brain metastases that are asymptomatic at screening and who are off or receiving low-dose (≤10 mg prednisone or equivalent) for at least 7 days prior to first dose of sevabertinib are eligible to enroll in Dose Escalation and Backfill.
    2. Participants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion/Extension (with the exception of Groups G and H) if all of the following criteria are met:

      • there is no evidence of progression (new or enlarging brain metastases) for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.
      • Participants must be off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent) for 7 days prior to first dose of sevabertinib.
    3. Participants with history of spinal cord compression >3 months from definitive therapy and stable by imaging (MRI or CT) during the screening period and clinically asymptomatic.
    4. Expansion Group G and Group H: Participants with active (new or progressing) clinically stable brain metastases who do not require immediate CNS-directed treatment as per Investigator's judgement and who are off or receiving low-dose corticosteroids (≤10 mg prednisone or equivalent such as ≤ 1.5 mg/day dexamethasone) in the 7 days prior to first dose of sevabertinib are eligible.
  • History of congestive heart failure (CHF) Class >II according to the (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment (e.g. ventricular arrhythmias, atrial fibrillation) or any abnormalities in rhythm, conduction or morphology or resting (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec).
  • Participants with:

    1. Known (HIV), except as noted below: Participants with history of HIV infection are eligible at the Investigator's discretion provided that: • CD4+ T-cell (CD4+) counts are ≥ 350 cells/uL • The participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to the start of study drug and has an HIV viral load less than 400 copies/mL prior to start of the study treatment • The ART being used does not contain strong inducers or inhibitors of , and is not anticipated to cause overlapping toxicities with study drug • The participant has not had an opportunistic infection within the past 12 months
    2. Active infection (positive for Hepatitis B surface antigen [HbsAg]) and Hepatitis B virus [HBV] DNA).
    3. Active infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay).

      NOTE: Participants with history of chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.

  • Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.

    Drug: BAY2927088_formulation A · Drug: BAY2927088_formulation B_1 · Drug: BAY2927088_formulation B_2

  • Experimental
    Backfill

    Dose Escalation and Backfill run concurrently

    Drug: BAY2927088_formulation A · Drug: BAY2927088_formulation B_1 · Drug: BAY2927088_formulation B_2

  • Experimental
    Dose expansion

    Eight independent groups (group A, B1, B2, C, D, E, F, G, H, I, J) are planned. Dose Expansion may start at a dose level that has been evaluated in Escalation/Backfill in at least 9 participants and considered safe or at any other dose levels that are below the highest dose level that is considered safe.

    Drug: BAY2927088_formulation B_1 · Drug: BAY2927088_formulation B_2 · Drug: BAY2927088_formulation B_3

  • Experimental
    Extension part

    Initiation of the Extension part will depend on the benefit-risk profile observed during Dose Expansion. Additionally, enrollment may be prematurely terminated based on emerging data at the discretion of the Sponsor.

    Drug: BAY2927088_formulation B_1 · Drug: BAY2927088_formulation B_2

Interventions

  • DrugBAY2927088_formulation A

    Oral administration

  • DrugBAY2927088_formulation B_1

    Oral administration

  • DrugBAY2927088_formulation B_2

    Oral administration

  • DrugBAY2927088_formulation B_3

    Oral administration

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to 30 days after the last administration of study treatment

  2. Number of participants with treatment-emergent serious adverse events (TESAEs)

    Time frame: Up to 30 days after the last administration of study treatment

  3. Severity of TEAEs

    Time frame: Up to 30 days after the last administration of study treatment

  4. Severity of TESAEs

    Time frame: Up to 30 days after the last administration of study treatment

  5. Number of participants who discontinue study treatment due to an AE

    Time frame: About 4 years (Up to the end of study treatment)

  6. Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BAY2927088 within the DLT observation period in Dose Escalation (including participants from Backfill qualifying for the MTD population)

    Time frame: At the end of Cycle 1 of a 21-day cycle

  7. Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level associated with administration of BAY2927088 in the DLT observation period in Dose Escalation (including participants from Backfill)

    In Dose Escalation (including participants from Backfill)

    Time frame: At the end of Cycle 1 of a 21-day cycle

  8. Cmax of BAY2927088

    Cmax: Maximum/peak concentration

    Time frame: Cycle 1, Day 1 (Cycle duration is 21 days)

  9. AUC(0-24) of BAY2927088 for QD

    AUC: Area under the concentration vs. time curve. AUC(0-24): AUC from time 0 to 24 hours post dose. QD: Quaque die (once daily)

    Time frame: Cycle 1, Day 1 (Cycle duration is 21 days)

  10. AUC(0-12) of BAY2927088 for BID

    If applicable. AUC(0-12): AUC from time 0 to 12 hours post dose. BID: Bis in die, 2 times daily.

    Time frame: Cycle 1, Day 1 (Cycle duration is 21 days)

  11. Cmax,md of BAY2927088

    Cmax,md: Cmax after multiple dose administrations

    Time frame: Cycle 1, Day 15 (Cycle duration is 21 days)

  12. AUC(0-24)md of BAY2927088 for QD

    AUC(0-24)md: AUC(0-24) after multiple dose administrations

    Time frame: Cycle 1, Day 15 (Cycle duration is 21 days)

  13. AUC(0-12)md of BAY2927088 for BID

    If applicable AUC(0-12)md: AUC(0-12) after multiple dose administrations

    Time frame: Cycle 1, Day 15 (Cycle duration is 21 days)

  14. Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR) in extension part

    Time frame: From the start of the study treatment up to 12 months

Secondary outcomes

  1. Overall response rate (ORR) as per RECIST v1.1 by investigator assessment

    RECIST v1.1: Response Evaluation Criteria in Solid Tumors, version 1.1

    Time frame: About 4 years

  2. Recommended phase 2 dose (RP2D) of BAY2927088

    Time frame: About 1.5 years

  3. ORR per RECIST v1.1 by Investigator assessment in extension part

    Time frame: From the start of the study treatment up to 12 months

  4. Disease control rate (DCR) per RECIST v1.1 by Investigator assessment and BICR in extension part

    Time frame: From the start of the study treatment up to 12 months

  5. Duration of response (DOR) per RECIST 1.1 by Investigator assessment and BICR in extension part

    Time frame: From the start of the study treatment up to 12 months

  6. Progression-free survival (PFS) per RECIST 1.1 by Investigator assessment and BICR in extension part

    Time frame: From the start of the study treatment up to 12 months

  7. Overall survival (OS) in extension part

    Time frame: From the start of the study treatment up to 12 months

  8. Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) categorized by severity in extension part

    Time frame: Up to 30 days after the last administration of study treatment

07

Study locations

3 of 94 sites recruiting
  • Banner MD Anderson Cancer Center at Banner Gateway Medical Center
    Gilbert, Arizona 85234, United States
    Completed

    Not enrolling at this site — choose another above.

  • City of Hope - Duarte Cancer Center
    Duarte, California 91010, United States
    Completed

    Not enrolling at this site — choose another above.

  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Dana-Farber Cancer Institute - Oncology Department
    Boston, Massachusetts 02215, United States
    Completed

    Not enrolling at this site — choose another above.

  • Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit
    Detroit, Michigan 48202, United States
    Completed

    Not enrolling at this site — choose another above.

  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Tennessee Oncology - Nashville Centennial Clinic
    Nashville, Tennessee 37203, United States
    Recruiting
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center
    Houston, Texas 77030, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Inova Schar Cancer Insitute - Inova Fairfax Hospital
    Fairfax, Washington 22031, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Virginia Cancer Specialists, PC - Fairfax
    Fairfax, Washington 22031, United States
    Completed

    Not enrolling at this site — choose another above.

  • UZ Leuven Gasthuisberg - Pneumology Department
    Leuven, Flemish Brabant 3000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AZ Delta | Clinical Trial Center - Pneumology
    Roeselare, West Flanders 8800, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
    Natal, Rio Grande do Norte 59040-000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Israelita Albert Einstein | Morumbi - Clinical Research Department
    São Paulo, 05651-901, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Beijing Cancer Hospital - Oncology Department
    Beijing, Beijing Municipality 100142, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
    Terminated

    Not enrolling at this site — choose another above.

  • Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech
    Wuhan, Hubei 430023, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hunan Cancer Hospital - Oncology Department
    Changsha, Hunan 410013, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province
    Taizhou, Jiangsu 317000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Terminated

    Not enrolling at this site — choose another above.

  • Shandong University - Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shanghai Chest Hospital, Shanghai Jiaotong University
    Shanghai, Shanghai Municipality 200030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • West China Hospital Sichuan University
    Chengdu, Sichuan 610041, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
    Hangzhou, Zhejiang 310016, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UNICANCER - Centre Leon-Berard (CLB) - Medical oncology
    Lyon, Auvergne-Rhône-Alpes 69373, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
    Bordeaux, New Aquitaine 33000, France
    Completed

    Not enrolling at this site — choose another above.

  • Hopital Nord Laennec - Oncologie medicale thoracique et digestive
    Nantes, Pays de la Loire Region 44093, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale
    Saint-Herblain, Pays de la Loire Region 44800, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AP-HM - Hopital de la Timone - Centre d'Essais en Cancerologie
    Marseille, Provence-Alpes-Côte d'Azur Region 13005, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Institut Curie - Paris - Oncologie medicale
    Paris, Île-de-France Region 75248, France
    Completed

    Not enrolling at this site — choose another above.

  • Gustave Roussy - Departement Oncologie-Radiotherapie
    Villejuif, Île-de-France Region 94805, France
    Completed

    Not enrolling at this site — choose another above.

  • Prince of Wales Hospital
    Hong Kong, Hong Kong SAR 00000, Hong Kong
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Queen Mary Hospital
    Hong Kong, Hong Kong SAR 00000, Hong Kong
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hong Kong United Oncology Centre
    Kowloon, 00000, Hong Kong
    Recruiting
  • Rabin Medical Center | Beilinson Campus
    Petah Tikva, Central District 4941492, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Chaim Sheba Medical Center
    Ramat Gan, Tel Aviv 5262000, Israel
    Completed

    Not enrolling at this site — choose another above.

  • IRCCS Istituto Nazionale Tumori Fondazione Pascale
    Naples, Campania 80131, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica
    Parma, Emilia-Romagna 43126, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
    Aviano, Friuli Venezia Giulia 33081, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
    Rome, Lazio 00128, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
    Milan, Lombardy 20133, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative
    Milan, Lombardy 20141, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    Rozzano, Lombardy 20089, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica
    Orbassano, Piedmont 10043, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia
    Verona, Veneto 37134, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Aichi Cancer Center Hospital
    Nagoya, Aichi-ken 464-8681, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kanagawa Cancer Center
    Yokohama, Kanagawa 241-8515, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kindai University Hospital
    Sakai, Osaka 590-0197, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shizuoka Cancer Center
    Sunto, Shizuoka 411-8777, Japan
    Completed

    Not enrolling at this site — choose another above.

  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tottori University Hospital
    Yonago, Tottori 683-8504, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Okayama University Hospital
    Okayama, 700-8558, Japan
    Terminated

    Not enrolling at this site — choose another above.

  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Radboud University Medical Center | Afdeling Interne Geneeskunde
    Nijmegen, Gelderland 6500 HB, Netherlands
    Withdrawn

    Not enrolling at this site — choose another above.

  • Nederlands Kanker Instituut
    Amsterdam, North Holland 1066 CX, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Erasmus University Medical Center | Research Department - Lung Diseases
    Rotterdam, South Holland 3015 GD, Netherlands
    Completed

    Not enrolling at this site — choose another above.

  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Łodzi
    Lodz, Łódź Voivodeship 92-213, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • START Research Portugal
    Lisbon, 1649-028, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Santa Maria | Centro de Investigacao Clinica
    Lisbon, 1649-035, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • IPO Porto
    Porto, 4200-072, Portugal
    Recruiting
  • National University Hospital Medical Centre
    Singapore, 119074, Singapore
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cancer Center Singapore - Oncology Department
    Singapore, 168583, Singapore
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Curie Oncology | Mount Elizabeth Novena
    Singapore, 329563, Singapore
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Seoul National University Bundang Hospital | Hematology and Medical Oncology
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • St Vincent's Hospital | Oncology
    Suwon, Gyeonggi-do 16247, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chungbuk National University Hospital | Hematology and Oncology
    Chungcheongbuk-do, North Chungcheong 28644, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Seoul National University Hospital | Oncology
    Jongno -Gu, Seoul 03080, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Severance Hospital | Oncology
    Seoul, 03722, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Asan Medical Center | Oncology
    Seoul, 05505, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Samsung Medical Center | Oncology
    Seoul, 06351, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Catala D'oncologia | Hospitalet | Oncologia
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitari Dexeus Grupo Quironsalud | Oncologia
    Barcelona, 08028, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitari Vall D Hebron | Oncologia
    Barcelona, 08035, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia
    Madrid, 28040, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Hm Sanchinarro | Oncologia
    Madrid, 28050, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario Virgen De La Victoria | Oncologia
    Málaga, 29010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario Y Politecnico La Fe | Oncologia
    Valencia, 46026, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chung Shan Medical University Hospital
    Taichung, 402306, Taiwan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chi-Mei Medical Center, Liouyine
    Tainan, 73657, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Taiwan University Hospital
    Taipei, 100, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Taipei Medical University (TMU) - Shuang Ho Hospital (SHH)
    Taipei, 23561, Taiwan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Chang Gung Memorial Hospital at Linkou
    Taoyuan, 33305, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Janne PA, Goto K, Ruttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Nov 6;393(18):1819-1832. doi: 10.1056/NEJMoa2511065. Epub 2025 Oct 17. PubMed 41104928 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2028, 85 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 85 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Dec 2028, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Oct 29, 2021
StartActual
Oct 25, 2021
Primary completionEst.
Dec 1, 2028was Mar 2026
CompletionEst.
Jun 30, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 14 sites removed
Show 16 added (9 Italy, 2 China, 2 Israel, 2 Poland, 1 Portugal)
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, China
  • Qilu Hospital of Shandong University · Jinan, China
  • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
  • Chaim Sheba Medical Center · Ramat Gan, Israel
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale · Naples, Italy
  • Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica · Parma, Italy
  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Rome, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
  • Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative · Milan, Italy
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica · Orbassano, Italy
  • Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia · Verona, Italy
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
  • Hospital Santa Maria | Centro de Investigacao Clinica · Lisbon, Portugal
Show 14 removed
  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School · Nanjing, China
  • Qilu Hosp., Shandong Univ. · Jinan, China
  • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
  • Chaim Sheba Medical Center · Ramat Gan, Israel
  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
  • Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative · Milan, Italy
  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica · Orbassano, Italy
  • Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica · Parma, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Roma, Italy
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
  • Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia · Verona, Italy
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
Oct 13, 2026
Primary completion
Mar 16, 2026→Dec 1, 2028
Oct 21, 2026
Enrollment
400→430
Oct 13, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedNote: Except for participants eligible for Group F, Group H and Group HI (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.
  • ChangedBefore Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments (or, for participants in Expansion Group G and Group H, for RANO-BM tumor assessments). Previously irradiated lesions must have shown progression to be considered measurable.Now Measurable disease by RECIST v1.1 (or by RANO-BM for participants in Expansion Groups G and H) with at least one lesion that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements.
Exclusion criteria
  • EditedParticipants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion/Extension (with the exception of GroupGroups G and Group H) if all of the following criteria are met:
Oct 13, 2026
Show all 3 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 21, 2026
    Primary completion Mar 16, 2026→Dec 1, 2028
    + 1 other change: verification date
  3. Oct 13, 2026
    16 sites added, 14 sites removed
    Show 16 added (9 Italy, 2 China, 2 Israel, 2 Poland, 1 Portugal)
    • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School · Nanjing, China
    • Qilu Hospital of Shandong University · Jinan, China
    • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
    • Chaim Sheba Medical Center · Ramat Gan, Israel
    • IRCCS Istituto Nazionale Tumori Fondazione Pascale · Naples, Italy
    • Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica · Parma, Italy
    • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Rome, Italy
    • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
    • Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative · Milan, Italy
    • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
    • Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica · Orbassano, Italy
    • Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia · Verona, Italy
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
    • Hospital Santa Maria | Centro de Investigacao Clinica · Lisbon, Portugal
    Show 14 removed
    • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School · Nanjing, China
    • Qilu Hosp., Shandong Univ. · Jinan, China
    • Rabin Medical Center | Beilinson Campus · Petah Tikva, Israel
    • Chaim Sheba Medical Center · Ramat Gan, Israel
    • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
    • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
    • Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative · Milan, Italy
    • Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica · Orbassano, Italy
    • Azienda Ospedaliero Universitaria Parma - SC Oncologia Medica · Parma, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Roma, Italy
    • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
    • Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia · Verona, Italy
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
    Enrollment 400→430
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedNote: Except for participants eligible for Group F, Group H and Group HI (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.
    • ChangedBefore Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments (or, for participants in Expansion Group G and Group H, for RANO-BM tumor assessments). Previously irradiated lesions must have shown progression to be considered measurable.Now Measurable disease by RECIST v1.1 (or by RANO-BM for participants in Expansion Groups G and H) with at least one lesion that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements.
    Exclusion criteria
    • EditedParticipants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion/Extension (with the exception of GroupGroups G and Group H) if all of the following criteria are met:
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05099172
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Oct 25, 2021
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
0018888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion